Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?
Keel purchased 4,701 shares at $53.18 each following a 21% year-long decline, signaling confidence in the medical device company's valuation.
Overview
Director Paul A. Keel purchased 4,701 shares of The Cooper Companies, Inc. (NASDAQ:COO) on Sept. 11, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($53.18); post-transaction value based on Sept. 11, 2026 market close ($53.91).
Details
The Cooper Companies is a global medical device manufacturer with approximately 15,000 employees and a market capitalization of $10.4 billion, positioning it as a significant player in the ophthalmic and vision care sector. The company's dual-segment strategy--combining contact lens innovation through CooperVision with surgical device offerings through CooperSurgical--provides diversified revenue streams and cross-selling opportunities within the eye care continuum. With trailing twelve-month (TTM) revenues of $4.2 billion and net income of $570.3 million, Cooper maintains a competitive edge through its extensive product portfolio addressing multiple vision correction modalities and its established relationships with eye care professionals globally.
Source
Originally published at www.fool.com.